Patents Assigned to GENEPOD THERAPEUTICS AB
  • Viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo
    Patent number: 9593312
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: March 14, 2017
    Assignee: Genepod Therapeutics AB
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik
  • Novel viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo
    Publication number: 20120309816
    Abstract: The present invention relates to a one-vector expression system comprising a sequence encoding two polypeptides, such as tyrosine hydroxylase (TH) and GTP-cyclohydrolase 1 (GCH1). The two polypeptides can be should preferentially be expressed at a ratio between 3:1 and 15:1, such as between 3:1 and 7:1. The invention is useful in the treatment of catecholamine deficient disorders, such as dopamine deficient disorders including but not limited to Parkinson's Disease. Moreover, the present invention provides a method to deliver the vector construct in order to limit the increased production of the catecholamine to the cells in need thereof.
    Type: Application
    Filed: November 9, 2010
    Publication date: December 6, 2012
    Applicant: GENEPOD THERAPEUTICS AB
    Inventors: Tomas Björklund, Anders Björklund, Deniz Kirik